Compositions that include hemagglutinin, methods of making and methods of use thereof

a technology of hemagglutinin and hemagglutinin, which is applied in the field of compositions that include hemagglutinin, methods of making and methods of use thereof, can solve the problems of ineffective prevention or treatment of illness, and achieve the effect of avoiding serious illness and death and cost effectiveness

Inactive Publication Date: 2007-09-27
VAXINNATE
View PDF48 Cites 59 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

[0028] The methods and composition of the invention can be employed to stimulate an immune response, in particular, a protective immune response, in a subject. Advantages of the claimed invention include, for example, cost effective methods and compositions that can be produced in relatively large quantities for use in the prevention and treatment of disease associated with viral influenza infection. The claimed methods and compositions can be employed to prevent or treat viral influenza infection and, therefore, avoid serious illness and death consequent to viral influenza infection.

Problems solved by technology

Viral influenza infection can lead to disease.
However, such strategies can be costly to maintain supply with demand and, thus, be limited in supply; may result in variable protection and less than satisfactory alleviation of symptoms, thereby ineffectively preventing or treating illness and, in some instances death, consequent to disease associated with viral influenza infection.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Compositions that include hemagglutinin, methods of making and methods of use thereof
  • Compositions that include hemagglutinin, methods of making and methods of use thereof
  • Compositions that include hemagglutinin, methods of making and methods of use thereof

Examples

Experimental program
Comparison scheme
Effect test

example 1

Design of Portions of a Naturally Occurring Hemagglutinin of Influenza A

Materials and Methods

[0361] Design of the HA1-1, 1-2 and 1-3 globular head constructs for A / Puerto Rico / 8 / 34 (H1N1). Influenza strain A / Puerto Rico / 8 / 34 (PR8) is a well-characterized mouse-adapted strain of influenza A virus. The published crystal structure of the mature PR8 HA (SEQ ID NO: 1) (Gamblin et al. 2005. Science 303:1838-1842; PDB accession number 1RU7) was used in combination with the Molecular Modeling Database to determine the boundaries for three PR8 globular head constructs. The complete list of solved crystal structures for influenza A hemagglutinin molecules can be found in the Protein Data Bank (PDB) or National Center for Biotechnology Information (NCBI) Structure website (http: / / www.ncbi.nlm.nih.gov / Structure).

[0362] The three dimensional crystal structure for the PR8 HA was viewed using the Cn3D program within the NCBI website. The trimeric HA molecule has the shape of a mushroom. The glo...

example 2

Design of Portions of a Naturally Occurring Hemagglutinin of Influenza B

Materials and Methods

[0395] Design of the HA1-1, 1-2 and 1-3 globular head constructs for B / Lee / 40. Structural considerations in the design of an influenza B HA vaccine are similar to those for influenza A, i.e., the domain boundary of the globular head of HA must be identified so that the flagellin-HA fusion protein can fold correctly or be refolded correctly to expose appropriate antigenic epitopes. Unlike influenza A, well-defined X-ray crystallographic structures are not available for influenza B HA, thus it is more difficult to unambiguously define the domain boundary of globular head. Therefore the influenza B HA model must be predicted based on bioinformatic and structural models (Tung et al. 2004. J. Gen. Virl. 85, 3249-3259). These investigators used a “knowledge-based” approach which depends on a high degree of sequence homology between the known structure from the protein data bank and the target un...

example 3

Cloning and Expression of Recombinant Flagellin-Hemagglutinin Fusion Proteins in E. coli

Materials and Methods

[0416] Cloning of HA influenza A subunits. Subunits of the HA globular head from several strains of influenza. A were cloned and expressed alone or as fusions with flagellin. We also expressed in fusion with the HA globular head domain, two proteins widely used as carrier proteins in conjugated vaccines. CRM-197 is a mutated diphtheria toxin (DTx) from Corynebacterium diphtheriae and LTB, is E. coli heat labile toxin B subunit.

[0417] These constructs were generated in one of four different methodologies:

[0418] Method #1: In this protocol, a fusion gene comprising flagellin (STF2) (SEQ ID NO: 212) and the HA subunit was codon-optimized for E. coli expression and obtained from a commercial vendor (DNA2.0 Inc., Menlo Park, Calif.) by chemical synthesis. The gene was excised with NdeI and BlpI enzymes, the insert fragment was gel purified and ligated to pET24a (Novagen, San D...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

PropertyMeasurementUnit
hydrophobicaaaaaaaaaa
solubilityaaaaaaaaaa
Login to view more

Abstract

Compositions comprise a flagellin component or a Toll-like Receptor agonist component that is at least a portion of a flagellin or a Toll-like Receptor agonist, wherein the flagellin component or Toll-like Receptor agonist component includes at least one cysteine residue and whereby the flagellin component or Toll-like Receptor agonist component activates a Toll-like Receptor 5 or Toll-like Receptor. Compositions comprise a flagellin component that is at least a portion of a flagellin, wherein at least one lysine of the flagellin component has been substituted with at least one arginine, serine and histidine, whereby the flagellin component activates Toll-like Receptor 5. Compositions can further include an antigen, such as an influenza antigen, a flavivirus antigen, a pathogen-related antigen, a bacterial capsular antigen and a carrier protein. The compositions are used to stimulate an immune response and a protective immune response in a subject.

Description

RELATED APPLICATIONS [0001] This application claims the benefit of U.S. Provisional Application Nos. 60 / 779,854, filed on Mar. 7, 2006; 60 / 784,497, filed on Mar. 20, 2006; 60 / 790,457, filed on Apr. 7, 2006; 60 / 814,292, filed on Jun. 16, 2006; 60 / 830,881, filed on Jul. 14, 2006; 60 / 838,007, filed on Aug. 16, 2006; and 60 / 856,451, filed on Nov. 3, 2006. The entire teachings of the above applications are incorporated herein by reference.BACKGROUND OF THE INVENTION [0002] Viral influenza infection can lead to disease. Strategies to prevent and manage disease associated with viral influenza infection can include vaccines with inactivated viruses and drugs. However, such strategies can be costly to maintain supply with demand and, thus, be limited in supply; may result in variable protection and less than satisfactory alleviation of symptoms, thereby ineffectively preventing or treating illness and, in some instances death, consequent to disease associated with viral influenza infection. ...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K39/295
CPCA61K39/00C12N15/62A61K39/0258A61K39/12A61K39/145A61K39/385A61K2039/6018A61K2039/6037A61K2039/6068A61K2039/6075C07K14/005C07K2319/00C12N2760/16122C12N2760/16134C12N2760/16222C12N2760/16234C12N2770/24122C07K14/11C07K14/195C07K14/255C12N2770/24134A61K39/02A61K47/42A61K2300/00C12N7/00A61P31/00A61P31/16A61P37/04Y02A50/30A61K2039/543A61K2039/575C12N2760/16171C12N2760/16271C12N2760/16322C12N2760/16334
Inventor POWELL, THOMAS J.PRICE, ALBERT E.NAKAAR, VALERIANEVANS, ROBERT K.
Owner VAXINNATE
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap